Welcome to Macroaxis
Sign in to go to your portfolios
Don't have an account? Create It
  Macroaxis: Personalized Investing   The proven technology to invest wisely
Macroaxis Country Selector USA  Change      Macroaxis User Registration Register    Macroaxis User Login Sign In
   
  
 
US Market Closed: May 25, 23:39 PM 2012  
FNMFO KDDIF 096770 AMKBF CTGBZ AU 
 
 
  NYSE  7,534  18.032  Index Moved Down 



Processing
Collecting data for DDSS

Labopharm media headlines

    
    

Labopharm Inc.

 Stock@American Stock Exchange 
United States
    
Use Labopharm Inc. media headlines together with your portfolio to protect against small markets fluctuations and to determine Stock optimization strategy that fits your criteria.
    
    

    
  

Labopharm Inc. Announces Reduction Of Angelini Labopharm's Oleptro Sales Force

Reuters Key Development - Jun 23, 2011
  
  

Labopharm Inc. Announces Intention To Delist From NASDAQ

Reuters Key Development - Jun 21, 2011
  
  

Labopharm Inc. Announces Workforce Reduction; Appoints Chief Financial Officer; Issues Q1 2011 Charge Guidance

Reuters Key Development - Mar 22, 2011
  
  

Labopharm Inc. Announces Appointment Of New President And CEO

Reuters Key Development - Mar 14, 2011
  
  

Labopharm Inc. Receives Health Canada Approval For Oleptro: A New Once-Daily Antidepressant For The Treatment ...

Reuters Key Development - Jan 20, 2011
  
  

Labopharm Inc. Monetizes Royalty Stream From Purdue For Ryzolt

Reuters Key Development - Jan 3, 2011
  
  

Labopharm Inc. And Paladin Labs Inc. Announce Expansion Of Commercial Relationship

Reuters Key Development - Oct 14, 2010
  
  

Labopharm Inc. Announces U.S. Launch Of OLEPTRO

Reuters Key Development - Aug 10, 2010
  
  

Labopharm Inc. Announces Completion Of Joint Venture With Angelini

Reuters Key Development - May 20, 2010
  
  

Labopharm Inc. And Gruppo Angelini To Establish Joint Venture To Commercialize OLEPTRO In The United States

Reuters Key Development - Apr 29, 2010
  
    

Discuss Labopharm media headlines

       
       

Labopharm Revenue

    
    

Labopharm Research Report

    
    

Labopharm Total Debt

Based on latest financial disclosure Labopharm Inc. has Total Debt of 0.0. This indicator is about the same for null average (which is currently at 0.0) sector, and about the same as debt (which currently averages 0.0) industry, This indicator is about the same for all stocks average (which is currently at 0.0).
In most industries, total debt may also include current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meaningful to compare total debt amounts between companies that operate within the same sector.
    
Follow Labopharm News with your standard RSS feed, custom widget, or your favorite social app
Add To Reader
 
Add Labopharm to your reader
 
Get social with Labopharm News
 Labopharm News 
Share Toggle social options for Labopharm News
    



 

 
Analytics
Investor Landscape
Efficient Frontier
Market Correlation
Risk and Return Analysis
Financial Content
Portfolio Projections
Portfolio Backtesting
Tools
FAQs
Retirement Optimizer
RSS and Mobile Access
Company Directory
Advisor Directory
Insider Directory
Wealth Management
About Us
About Macroaxis
Contact Us
Terms Of Use
Privacy Policy
Custom Reporting
Product Tour
More ROI Custom Reporting